TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Vera Therapeutics
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Vera Therapeutics submitted a Biologics License Application to the FDA for atacicept, a potential treatment for IgA Nephropathy, after successful Phase 3 trial results showing significant proteinuria reduction. The drug targets B-cell cytokines and could potentially be approved in 2026.

Insights
NKE   neutral

Mentioned as a traditional competitor in sports merchandising, with lower margins compared to Lululemon


VERA   positive

Company achieved significant clinical trial results, submitted BLA, and is advancing a potentially breakthrough treatment for a serious kidney disease